Docetaxel

← All agents

Catalog entry human-reviewed · each study below is labeled with how it was published · How we review →

AI extractedhuman reviewedsources checkedretractions suppressed

Get cited updates on Docetaxel

A monthly email when the research changes — $10/mo. Manage follows

Follow Docetaxel

Evidence at a glanceInsufficient evidenceMixed results⚠ Studies disagree

5 published studies tagged to this agent0 human studies approved & graded (trial, observational, or meta-analysis)

Why this grade?

Insufficient evidence — No primary experimental studies yet.

0 human · 0 animal · 0 lab · 5 review/other
Most authoritative study: Expert consensus: Profiling and management of advanced or metastatic epithelial ovarian cancer
Studies disagree on the reported direction (conflict flagged).
No human studies yet
Findings conflict across studies
Effect sizes reported in only 3 of 5 studies

Computed deterministically from the studies’ types and reported outcomes — not written by AI, and not a claim that anything works.

Auto-discovered · not yet curateddocetaxel

Educational only, not medical advice. OncoForge makes no claim that Docetaxel treats, prevents, or cures any condition, beyond what the linked studies show. Evidence levels vary; effects may not translate to people, and some compounds can cause harm. Always coordinate with your oncology team.

Simple Summary

Auto-discovered from 5 recent studies; not yet curated.

Research

Where the evidence is

What has been studied, and how strong it is, by topic. A dashed cell means no studies were found for that combination — a gap, not evidence of no effect. Open a row to see its studies.

CancerHuman evidenceMechanismSafetyTrial

Uterine Leiomyosarcoma—1——

Brain and lung metastasis of uterine leiomyosarcoma: illustrative case Case reportReported positive
Management of advanced uterine leiomyosarcoma ReviewMixed results

Advanced Or Metastatic High Grade Epithelial Ovarian Cancer—1—1

Expert consensus: Profiling and management of advanced or metastatic epithelial ovarian cancer ReviewInconclusive

Brain Metastasis————

Brain and lung metastasis of uterine leiomyosarcoma: illustrative case Case reportReported positive

High Grade Epithelial Ovarian Cancer—1—1

Expert consensus: Profiling and management of advanced or metastatic epithelial ovarian cancer ReviewInconclusive

Lung Metastasis————

Brain and lung metastasis of uterine leiomyosarcoma: illustrative case Case reportReported positive

Metastatic Prostatic Neoplasm (Lymph Nodes, Bone, Liver)————

Dermatomyositis associated with prostate adenocarcinoma with neuroendocrine differentiation Case reportReported positive

Ovarian Epithelial Carcinoma—1—1

Expert consensus: Profiling and management of advanced or metastatic epithelial ovarian cancer ReviewInconclusive

Ovarian Leiomyosarcoma————

Primary ovarian leiomyosarcoma: a case report Case reportReported negative

Prostate Adenocarcinoma With Neuroendocrine Differentiation————

Dermatomyositis associated with prostate adenocarcinoma with neuroendocrine differentiation Case reportReported positive

Sarcoma—1——

Management of advanced uterine leiomyosarcoma ReviewMixed results

Soft Tissue Sarcoma—1——

Management of advanced uterine leiomyosarcoma ReviewMixed results

Uterine Neoplasms—1——

Management of advanced uterine leiomyosarcoma ReviewMixed results

Reported figures

Study mix

5 published studies by what they were done in. Lab and animal findings often do not carry over to people.

5 Review/other

Reported directionReported positive2Mixed results1Reported negative1Inconclusive1

What supports this page

The kinds of sources behind this page, strongest at the top. Faint rungs show what is not here yet.

Guideline

Meta-analysis

Systematic review

Randomized trial

Clinical trial

Observational

Case report

Review

Preclinical

Other

5 studies5 review/other

Tracking 5 published studies of Docetaxel: 5 reviews/other.

Reported direction across studies: 2 positive, 1 mixed, 1 negative, 1 inconclusive.

Findings conflict — both supportive and negative/mixed results exist (see below). Human evidence is absent so far.

These counts summarize what the studies reported; they are not a measure of whether Docetaxel works.

Cancers named in these studies

uterine leiomyosarcoma (2)ovarian leiomyosarcoma (1)advanced or metastatic high-grade epithelial ovarian cancer (1)high-grade epithelial ovarian cancer (1)ovarian epithelial carcinoma (1)brain metastasis (1)lung metastasis (1)prostate adenocarcinoma with neuroendocrine differentiation (1)metastatic prostatic neoplasm (lymph nodes, bone, liver) (1)soft tissue sarcoma (1)

Conflicting evidence

Reported positive (2)

Brain and lung metastasis of uterine leiomyosarcoma: illustrative case
Case report · Limited evidence · May 2023
Dermatomyositis associated with prostate adenocarcinoma with neuroendocrine differentiation
Case report · Limited evidence · Jan 2021

Negative or mixed (2)

Primary ovarian leiomyosarcoma: a case report
Case report · Limited evidence · Sep 2024
Management of advanced uterine leiomyosarcoma
Review · Limited evidence · Jul 2014

All studies

Case reportReported negativeLimited evidenceTier 3 · early humann = 1

Primary ovarian leiomyosarcoma: a case report

The Journal of international medical research · Sep 2024 · case report

Docetaxel Gemcitabineovarian leiomyosarcoma

This is a case report of a woman in her late 50s diagnosed with primary ovarian leiomyosarcoma who underwent surgery. One month after surgery she received gemcitabine plus docetaxel chemotherapy for six months. Recurrence in the pelvic cavity was detected eight months after surgery. The report aims to raise awareness of this rare disease.

Reported effects: chemotherapy_duration 6 mo, n=1 · time_to_recurrence 8 mo, n=1

Studied with: gemcitabine + docetaxel.

Key findings

A woman in her late 50s presented with a 6-month history of abdominal pain and imaging revealed a pelvic mass.
She underwent surgery and was diagnosed with primary ovarian leiomyosarcoma.
One month postoperatively she began gemcitabine and docetaxel chemotherapy and continued this treatment for 6 months.
Eight months postoperatively recurrence was detected in the pelvic cavity.

Limitations: Single-patient case report (n=1), limiting generalizability; No chemotherapy doses or detailed regimen parameters provided; Short follow-up reported (recurrence at 8 months) with no long-term outcome data; No control or comparator group.

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text

ReviewTrialInconclusiveLimited evidenceTier 4 · clinicaln = 11

Expert consensus: Profiling and management of advanced or metastatic epithelial ovarian cancer

Revista colombiana de obstetricia y ginecologia · Jun 2024 · expert consensus / practice guideline based on literature review

Liposomal-doxorubicin Tamoxifen Paclitaxel Rucaparib Bevacizumab Anastrozole Cisplatin Gemcitabine Topotecan Docetaxel Niraparib Olaparib Carboplatinadvanced or metastatic high-grade epithelial ovarian cancerhigh-grade epithelial ovarian cancerovarian epithelial carcinoma

This paper is an expert consensus, not a clinical study of a single drug. Eleven specialists reviewed the literature and issued recommendations for managing advanced or metastatic high-grade epithelial ovarian cancer, including surgery, chemotherapy, genetic testing, bevacizumab, and PARP inhibitors. It does not report new patient outcomes from a trial. The document mainly summarizes what the panel suggested based on existing guidelines and evidence.

Studied with: platinum-based chemotherapy, bevacizumab, paclitaxel, carboplatin.

Key findings

The panel suggested primary cytoreductive surgery as the initial approach when complete resection is feasible.
Neoadjuvant chemotherapy followed by interval surgery was suggested when complete cytoreduction is unlikely or the patient has poor functional status/comorbidities.
Bevacizumab was suggested with platinum-based chemotherapy for high-risk disease, with maintenance only if it was part of first-line therapy.
PARP inhibitors (olaparib, niraparib, rucaparib) were suggested as maintenance in selected BRCA/HRD-defined groups.
For platinum-resistant relapse, sequential non-platinum single-agent chemotherapy and best supportive care for poor performance status were suggested.

Limitations: This is a consensus statement/practice guideline, not an original comparative trial.; No new efficacy or safety data are reported in the abstract.; Recommendations are based on literature review and expert agreement, so they are subject to guideline-selection and expert-opinion bias.; The abstract does not provide patient-level outcomes, follow-up, or effect estimates.; Several recommendations are conditional/suggested rather than based on direct evidence from this paper..

Provides management recommendations for advanced/metastatic epithelial ovarian cancer, including several anticancer agents and maintenance strategies.

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text

Case reportReported positiveLimited evidenceTier 3 · early humann = 1

Brain and lung metastasis of uterine leiomyosarcoma: illustrative case

Journal of neurosurgery. Case lessons · May 2023 · case report with literature review

Docetaxel Gemcitabineuterine leiomyosarcomabrain metastasislung metastasis

This is a case report of a 51-year-old woman whose uterine leiomyosarcoma metastasized to the brain 44 months after primary tumor resection. The patient underwent gross-total resection of the brain lesion followed by stereotactic radiosurgery and chemotherapy with gemcitabine and docetaxel; at 8 months after resection she was alive and without recurrence. The authors also reviewed previously reported cases and reported an apparent survival benefit associated with adjuvant radiation therapy.

Reported effects: time_to_brain_metastasis 44 mo, n=1 · follow_up_duration_alive 8 mo, n=1

Studied with: surgical resection (right occipital craniotomy, gross-total resection), stereotactic radiosurgery, chemotherapy (gemcitabine + docetaxel).

Key findings

A single brain lesion was discovered 44 months after resection of the primary uterine tumor.
The patient underwent right occipital craniotomy with gross-total resection and received adjuvant stereotactic radiosurgery and chemotherapy with gemcitabine and docetaxel.
At 8 months postresection the patient remained alive and asymptomatic with no sign of recurrence.
In a literature review of prior reported cases, the authors found an apparent survival benefit in patients receiving adjuvant radiation therapy.

Limitations: Single-patient case report (n=1), so findings are not generalizable.; Short reported follow-up (8 months) limits assessment of long-term outcomes.; Literature review methods are not described in the abstract (potentially non-systematic and subject to bias).; No control group or randomized comparison to establish causality for the observed outcomes.; No chemotherapy dosing or detailed regimen schedule reported in the abstract..

Report of metastatic uterine leiomyosarcoma involving the brain with surgical and adjuvant therapy and a literature review suggesting possible benefit of adjuvant radiation.

AI summary of the abstract, human-reviewed · Sep 2026. Describes what this study reported, not medical advice. View on PubMed · Full text

Case reportSupportive careReported positiveLimited evidenceTier 3 · early humann = 1

Dermatomyositis associated with prostate adenocarcinoma with neuroendocrine differentiation

BMC urology · Jan 2021 · case report

Docetaxel Etoposide Cisplatinprostate adenocarcinoma with neuroendocrine differentiationmetastatic prostatic neoplasm (lymph nodes, bone, liver)

This case report describes a 63-year-old man with metastatic prostate adenocarcinoma with neuroendocrine differentiation who developed dermatomyositis shortly after starting androgen deprivation therapy. He received high-dose glucocorticoids for dermatomyositis and chemotherapy with etoposide and cisplatin; PSA and NSE fell and metastases were reduced, and the dermatomyositis improved allowing return of oral intake. Later therapies (docetaxel, abiraterone, enzalutamide) were used sequentially; dermatomyositis worsened temporarily on abiraterone but improved after switching to enzalutamide and increasing glucocorticoids.

Reported effects: patient_age 63, n=1 · time_to_dermatomyositis_onset 2, n=1

Studied with: etoposide + cisplatin (EP), ADT followed by EP, sequential docetaxel, abiraterone, enzalutamide.

Key findings

A 63-year-old man presented with pollakiuria and high PSA and NSE.
Prostate biopsy showed adenocarcinoma with neuroendocrine differentiation and multiple metastases to lymph nodes, bone, and liver.
Androgen deprivation therapy (ADT) was started immediately.
Following 2 ndnbsp;weeks of treatment, erythema on the skin and muscle weakness with severe dysphagia appeared and the patient was diagnosed with dermatomyositis.
High-dose glucocorticoid therapy was initiated for dermatomyositis.
ADT and subsequent chemotherapy with etoposide and cisplatin (EP) decreased PSA and NSE and reduced all metastases.
After initiation of EP therapy, dermatomyositis improved and the patient regained oral intake function.
EP was later replaced by docetaxel, abiraterone, and enzalutamide because of adverse events; no consistent cancer progression was observed.
Dermatomyositis worsened temporarily during abiraterone administration but improved after switching to enzalutamide and escalating glucocorticoid dose.

Limitations: Single-patient case report; findings may not generalize.; No control or comparator group.; No doses, objective outcome scales, or detailed timelines provided in the abstract.; Causality between cancer treatment changes and dermatomyositis course cannot be established from this report.; Duration and long-term follow-up are not specified in the abstract..

Describes a paraneoplastic dermatomyositis case in metastatic prostate adenocarcinoma with neuroendocrine differentiation and reports clinical course with cancer-directed therapies and steroids.

AI summary of the abstract, human-reviewed · Sep 2026. Describes what this study reported, not medical advice. View on PubMed · Full text

ReviewMixed resultsLimited evidenceTier 4 · clinical

Management of advanced uterine leiomyosarcoma

Current opinion in oncology · Jul 2014 · narrative review

Docetaxel Dacarbazine Ifosfamide Doxorubicinuterine leiomyosarcomasoft tissue sarcomauterine neoplasmssarcoma

This narrative review summarizes evidence-based management of recurrent and metastatic uterine leiomyosarcoma. For disseminated disease the authors state fixed‑dose‑rate gemcitabine plus docetaxel is an appropriate first-line chemotherapy and list other active cytotoxic agents (doxorubicin, ifosfamide, dacarbazine). They note trabectedin and other targeted therapies are under investigation (pazopanib is currently the only approved targeted therapy for advanced soft tissue sarcoma) and that aromatase inhibitors may be reasonable for small-volume, slowly progressive ER/PR-positive disease. The authors conclude overall survival for advanced disease remains poor and novel agents are needed.

Studied with: fixed-dose-rate gemcitabine plus docetaxel.

Key findings

Selected patients with localized or single-organ oligometastatic disease may benefit from surgical resection.
For patients with disseminated disease, fixed-dose-rate gemcitabine plus docetaxel is an appropriate first-line chemotherapy regimen.
Other active cytotoxic agents include doxorubicin, ifosfamide, and dacarbazine.
The role of trabectedin is being explored; trabectedin is approved by the European Medicine Agency to be marketed for advanced or metastatic soft tissue sarcoma.
Trials are underway for targeted therapy in uterine LMS; currently, the only approved targeted therapy for advanced soft tissue sarcoma is pazopanib.
In patients with small volume and slowly progressive estrogen receptor/progesterone receptor-positive disease, antiestrogen therapy with an aromatase inhibitor is a reasonable alternative to observation alone.
Despite recent advances, overall survival for advanced disease remains poor and identification of novel agents with activity in LMS is needed.

Limitations: Narrative review rather than primary data or systematic review; no new quantitative results presented in this article.; Conclusions depend on the quantity and quality of existing trials, which are not detailed in the abstract.; No sample sizes, effect sizes, or trial-level data are reported in the abstract to support comparative effectiveness claims..

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed

What changed recently

The latest additions to Docetaxel's evidence base, and anything that's been retracted.

Recently added

Dermatomyositis associated with prostate adenocarcinoma with neuroendocrine differentiation Case report · added Sep 2026
Brain and lung metastasis of uterine leiomyosarcoma: illustrative case Case report · added Sep 2026
Management of advanced uterine leiomyosarcoma Review · added Jun 2026
Primary ovarian leiomyosarcoma: a case report Case report · added Jun 2026
Expert consensus: Profiling and management of advanced or metastatic epithelial ovarian cancer Review · added Jun 2026

Cancers where Docetaxel reported positive results

Where at least one study reported a positive result, shown with the full picture, not just the wins. Positive results are more likely to be published, and most of these are early lab or animal studies that may not translate to people. This reports what studies found, not what works.

Preclinical only: lab / animal (5)

Uterine leiomyosarcoma1 positive1 negative/mixed

Cited positive studies (1)

Brain and lung metastasis of uterine leiomyosarcoma: illustrative case Case report · May 2023

Brain metastasis1 positive

Cited positive studies (1)

Brain and lung metastasis of uterine leiomyosarcoma: illustrative case Case report · May 2023

Lung metastasis1 positive

Cited positive studies (1)

Brain and lung metastasis of uterine leiomyosarcoma: illustrative case Case report · May 2023

Prostate adenocarcinoma with neuroendocrine differentiation1 positive

Cited positive studies (1)

Dermatomyositis associated with prostate adenocarcinoma with neuroendocrine differentiation Case report · Jan 2021

Metastatic prostatic neoplasm (lymph nodes, bone, liver)1 positive

Cited positive studies (1)

Dermatomyositis associated with prostate adenocarcinoma with neuroendocrine differentiation Case report · Jan 2021

Evidence at a glance: Docetaxel by cancer

A deterministic grade of what published studies report for each: strength of evidence, the reported direction, and the largest credible effect, strongest-evidence first. This summarizes findings; it is not a claim that anything works.

Uterine leiomyosarcomaInsufficient evidenceMixed results